Akebia Therapeutics, Inc.
No SEC Form 4 filings for $AKBA in the last 30 days.
See all $AKBA insider activity →Akebia Therapeutics' Chief Commercial Officer Nicholas Grund will resign on November 6, 2026, and serve as a consultant until April 30, 2027, according to an SEC filing.
Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “
Akebia Therapeutics (AKBA) dosed the first patient in a Phase 2 trial of ebribafusp for rare kidney diseases. The trial will enroll up to 30 patients and evaluate safety, proteinuria, and kidney function. Ebribafusp aims to inhibit complement activation in kidney tissue. Initial data is expected in 2027. AKBA's stock is currently at $0.90, down 4.87%.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AKBA (Akebia Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent AKBA coverage spans financial news, corporate actions and technology.
Executive resignation may cause modest short‑term stock pressure as investors reassess commercial leadership.
The departure of a senior commercial executive may raise short‑term uncertainty about the company's go‑to‑market strategy.
Initiation of Phase 2 dosing signals progression of a novel complement‑targeted therapy, potentially de‑risking the program and supporting future valuation.
Near-term trading focus is on Vafseo commercial momentum and the VOICE safety readout, offset by Auryxia revenue decline and higher operating costs.
The 8-K discloses shareholder-approved increases to authorized capital, which can enable future equity issuance and dilute holders.
AlphAI scores every news story that mentions AKBA with an AI model for sentiment and relevance, and aggregates insider trades from Akebia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Akebia Therapeutics' Chief Commercial Officer Nicholas Grund will resign on November 6, 2026, and serve as a consultant until April 30, 2027, according to an SEC filing.
1 min readAkebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “
1 min readAkebia Therapeutics (AKBA) dosed the first patient in a Phase 2 trial of ebribafusp for rare kidney diseases. The trial will enroll up to 30 patients and evaluate safety, proteinuria, and kidney function. Ebribafusp aims to inhibit complement activation in kidney tissue. Initial data is expected in 2027. AKBA's stock is currently at $0.90, down 4.87%.
1 min readAkebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with ini
6 min readAkebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. akba-20260617 0001517022 FALSE 0001517022 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date
2 min readAkebia Therapeutics is seeking shareholder approval to significantly increase its authorized common shares from 350 million to 500 million, and total capital stock from 375 million to 525 million, at its virtual 2026 annual meeting on June 17, 2026. This move aims to provide the company with greater flexibility for future financing, strategic deals, and equity incentives without requiring further charter amendments. Shareholders will also vote on director elections, executive compensation, its frequency, and the ratification of Ernst & Young LLP as the independent auditor.
4 min readAkebia Therapeutics has announced that the first patient has been dosed in a Phase 2 clinical trial for praliciguat, a soluble guanylate cyclase (sGC) stimulator. This drug is being evaluated for the treatment of biopsy-confirmed FSGS, a rare kidney disease, with potential future applications for other rare podocytopathies. There are currently no approved treatments for FSGS, which impacts approximately 40,000 patients in the U.S., and praliciguat has shown no significant safety issues in previous Phase 1 and 2 studies.
2 min readInvestors need to pay close attention to AKBA stock based on the movements in the options market lately.
3 min readThe heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
3 min readCAMBRIDGE, Mass., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. ( NASDAQ:AKBA ) , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the presentation of a post-hoc win odds analysis of all-cause mortality and ...
2 min read
